Qiming Corporate GP VI, Ltd. sold $4.8M of ALMR (indirect holdings)
Qiming Corporate GP VI, Ltd. sold 173,673 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $27.73 ($27.02–$28.26, $4.82M total) across 12 trades over 2026-10-15 to 2026-10-16. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).
How this was made
The 30-second read
Why it matters
The disclosed sale reduces the insider's ownership but does not indicate a change in control or major corporate action.
Market read
Primary insider sale of a micro‑cap biotech; modest relevance for short‑term traders monitoring insider activity.
What to watch
Potential upcoming clinical data or financing needs not disclosed may be driving the sale.
Background
SEC Form 4 filings disclose insider transactions; investors monitor them for signals about company prospects.
Ticker impact
Form 4 shows Qiming Corporate GP VI, Ltd. sold ~173,673 shares of ALMR for $4.8M, reducing its stake to 1.89M shares.
likely modest downward pressure as the market prices the insider sell
The sale is sizable for a micro‑cap but not large enough to move the market dramatically; insider sales often trigger short‑term selling pressure.
Market effects
Minimal impact on the broader biotech sector; only reflects a single shareholder's disposition.
No regional effect; the filing is specific to ALMR.
Limited global relevance; micro‑cap insider transaction.
Counterpoint
The sale could be a routine portfolio rebalancing rather than a negative signal.
Key entities
- companyAlamar Biosciences, Inc.
Biotech firm listed on NASDAQ under ticker ALMR.
- insiderQiming Corporate GP VI, Ltd.
10% owner of ALMR filing the sale.
